The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 19, 2023

Filed:

May. 19, 2021
Applicant:

Aligos Therapeutics, Inc., South San Francisco, CA (US);

Inventors:

Tongfei Wu, Boortmeerbeek, BE;

Pierre Jean-Marie Bernard Raboisson, Wavre, FR;

Antitsa Dimitrova Stoycheva, Half Moon Bay, CA (US);

Francois Gonzalvez, Antwerp, BE;

Jerome Deval, Pacifica, CA (US);

Cheng Liu, Burlingame, CA (US);

Assignee:

Aligos Therapeutics, Inc., South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 519/00 (2006.01); C07C 229/16 (2006.01); C07C 215/14 (2006.01); C07D 233/36 (2006.01); C07D 207/267 (2006.01); C07D 295/135 (2006.01); C07D 217/02 (2006.01); C07D 209/44 (2006.01); C07C 211/42 (2006.01); C07D 205/12 (2006.01); C07D 491/107 (2006.01); C07D 217/04 (2006.01); C07D 401/14 (2006.01); C07D 471/04 (2006.01); C07C 233/36 (2006.01);
U.S. Cl.
CPC ...
C07D 519/00 (2013.01); C07C 211/42 (2013.01); C07C 215/14 (2013.01); C07C 229/16 (2013.01); C07C 233/36 (2013.01); C07D 205/12 (2013.01); C07D 207/267 (2013.01); C07D 209/44 (2013.01); C07D 217/02 (2013.01); C07D 217/04 (2013.01); C07D 295/135 (2013.01); C07D 401/14 (2013.01); C07D 471/04 (2013.01); C07D 491/107 (2013.01); C07C 2602/08 (2017.05);
Abstract

The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.


Find Patent Forward Citations

Loading…